

**Vector CMVR Containing the Murine Anti-Middle East Respiratory Syndrome Coronavirus Spike Monoclonal Antibody G4 Light Chain Gene**

**Catalog No. NR-52031**

This reagent is the tangible property of the U.S. Government.

**For research use only. Not for use in humans.**

**Contributor:**

Barney Graham, Deputy Director and Chief, Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA

**Manufacturer:**

BEI Resources

**Product Description:**

NR-52031 is an expression vector containing a 717 base pair (VL+CL) insert that encodes a murine anti-Middle East respiratory syndrome coronavirus (MERS-CoV) spike (S) monoclonal antibody G4 light chain gene.<sup>1,2,3</sup> The vector contains regulatory elements CMV enhancer/promoter, CMV IE splicing acceptor and HTLV-1 R region/splicing donor. murine Ig light chain leader is provided as the targeting sequence. The kanamycin resistance gene, *aph*, provides transformant selection through kanamycin resistance in *Escherichia coli* (*E. coli*). The resulting size of the plasmid is approximately 5100 base pairs. The complete plasmid sequence and map are provided on the BEI Resources webpage. The plasmid was produced in *E. coli* and extracted.

The murine monoclonal antibody was isolated from a hybridoma generated from mice primed with plasmid vaccine encoding full-length S DNA and boosted with S1 protein. Clone G4 binds to S2 subunit.<sup>2</sup>

The S glycoprotein mediates viral binding to the host dipeptidyl-peptidase 4 (DPP4). This protein forms a trimer, and when bound to a host receptor, allows fusion of the viral and cellular membranes. The S protein is a target for neutralizing antibodies.<sup>4</sup>

**Material Provided:**

Each vial contains plasmid DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The DNA concentration and volume provided are shown on the Certificate of Analysis. The vial should be centrifuged prior to opening. Note: The contents of the vial should be used to replicate the plasmid in *E. coli* prior to mammalian expression.

**Packaging/Storage:**

NR-52031 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

**Citation:**

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Vector CMVR Containing the Murine Anti-Middle East Respiratory Syndrome Coronavirus Spike Monoclonal Antibody G4 Light Chain Gene, NR-52031.”

**Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

NR-52031 is claimed in U.S. Patent No. 7,094,598 and U.S. Patent Application No. 15/553,466 and the continuations, continuations-in-part, re-issues and foreign counterparts thereof.<sup>5,6</sup> NR-52031 cannot be transferred to for-profit entities.

**References:**

1. Graham, B., Personal Communication.
2. Wang, L., et al. "Evaluation of Candidate Vaccine Approaches for MERS-CoV." Nat. Commun. 6 (2015) PubMed: 26218507.
3. Wang, L., et al. "Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein to Avoid Neutralization Escape." J. Virol. 92 (2018): e02002-17. PubMed: 29514901.
4. Rabaan, A. A., et al. "SARS-CoV-2, SARS-CoV, and MERS-COV: A Comparative Overview." Infez. Med. 1 (2020): 174-184. PubMed: 32275259.
5. Graham, B., et al. "Middle East Respiratory Syndrome Coronavirus Immunogens, Antibodies, and their Use." U.S. Patent Application 15/553466, 2018.
6. Nabel, G. J. and Z. Yang. "Development of a Preventive Vaccine for Filovirus Infection in Primate." U.S. Patent No. 7094598, 2006.

ATCC® is a trademark of the American Type Culture Collection.

